clinical trial · NCT07580339
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·not yet recruiting·n = 30
Rectal CancerDCSZ11RadiationCapecitabineOxaliplatin
brief summary
The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR) high risk locally advanced rectal cancer.
started
Jul 1, 2026
primary completion
Jul 1, 2030
completion
Jul 1, 2030
last updated
May 12, 2026
official title
Combining CD93 Inhibition (DCSZ11) With Short Course Radiation and Chemotherapy as Part of Total Neoadjuvant Treatment (TNT) for High-risk Mismatch Repair Proficient (pMMR) Locally Advanced Rectal Cancer (LARC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol